Drug Profile
Ruzasvir - Atea Pharmaceuticals
Alternative Names: MK-8408; RZRLatest Information Update: 10 Jan 2024
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Developer Atea Pharmaceuticals; Merck Sharp & Dohme
- Class Antivirals; Benzoxazines; Carbamates; Cyclopropanes; Esters; Imidazoles; Indoles; Pyrrolidines; Thiazoles
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis C
Most Recent Events
- 09 Jan 2024 Efficacy and adverse events data from a phase II trial in Hepatitis C infection released by Atea Pharmaceuticals
- 13 Nov 2023 Pharmacodynamics data from a preclinical study in Hepatitis C released by Atea Pharmaceuticals
- 13 Nov 2023 Pharmacokinetic and adverse events data from a phase I drug-drug interaction trial released by Atea Pharmaceuticals